BA0610, BOSTER, China)
Understanding these mechanisms more precisely could lead to the development of targeted strategies to mitigate these effects or the creation of new formulations of the drug with reduced gastrointestinal impact
Tirzepatide-based evidence from the SURPASS (Researching Tirzepatide in Patients with Type 2 Diabetes for Glycemic Control and Weight Management) trials (SURPASS-1 NCT03954834 and SURPASS-5 NCT04039503) demonstrated dose-dependent, significant weight loss over 40 weeks compared with placebo, along with reductions in BMI and waist circumference [62, 63]
doi: 10.1016/j.canlet.2014.04.018
While relationships were not as robust as for the matched-time analyses, fasting levels of 17 metabolites were positively correlated with glucose at 120 minutes, including lactate, AAs (Gln, Pro, Trp, Tyr, betaine), carnitine, and multiple lipids (lysophosphatidylcholine [LPC] 18:0, 18:2, 20:3, and 22:6